Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease

Area of Science:

• Hepatology
• Mitochondrial Biology
• Metabolic Diseases

Background:

• Nonalcoholic fatty liver disease (NAFLD) is a prevalent global health issue affecting a quarter of the world's population.
• NAFLD encompasses a spectrum of liver conditions, from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma.
• Metabolic dysregulation, including obesity and type 2 diabetes, is strongly linked to NAFLD pathogenesis, leading to the proposed term metabolic (dysfunction)-associated fatty liver disease (MAFLD).

Purpose of the Study:

• To review the current understanding of NAFLD pathogenesis.
• To highlight the critical role of mitochondrial dysfunction in NAFLD development and progression.
• To explore therapeutic strategies targeting mitochondria for NAFLD/NASH treatment.

Main Methods:

• Review of existing literature on NAFLD and mitochondrial function.
• Analysis of data from animal models and human subjects.
• Discussion of evidence linking mitochondrial dysfunction to NAFLD.

Main Results:

• Mitochondrial dysfunction, including impaired fatty acid oxidation and reduced mitochondrial quality, is a key factor in NAFLD.
• Evidence from both animal models and human studies supports the role of mitochondrial dysfunction in NAFLD.
• Modifying mitochondrial function has shown potential in modulating NAFLD.

Conclusions:

• Mitochondrial dysfunction is central to the pathogenesis of NAFLD/MAFLD.
• Targeting mitochondrial pathways represents a promising therapeutic avenue for NAFLD/NASH.
• Further research into mitochondrial-targeted therapies could lead to effective treatments for these liver conditions.